HCG, five independent molecules

Clinica Chimica Acta

Volumn 413, Issue 1-2, 2012, Pages 48-65

  Cole, Laurence A ^a  

^a USA hCG Reference Service Reference Service   (United States)

Author keywords

HCG; HCG ; Human chorionic gonadotropin; Hyperglycosylated hCG; Hyperglycosylated hCG ; Sulfated hCG

Indexed keywords

CHORIONIC GONADOTROPIN; HYPOPHYSIS HORMONE;

AMINO ACID SEQUENCE; AUTOCRINE EFFECT; CANCER INVASION; CELL TRANSFORMATION; CHORIOCARCINOMA; DISEASE ACTIVITY; DOWN SYNDROME; FALSE POSITIVE RESULT; GENETIC SCREENING; GONADOTROPIN SECRETING CELL; HORMONE ACTION; HORMONE DETERMINATION; HORMONE METABOLISM; HORMONE STRUCTURE; HUMAN; HYPOPHYSIS CELL; MALIGNANT NEOPLASTIC DISEASE; MENOPAUSE; MOLECULAR BIOLOGY; MOLECULAR EVOLUTION; MOLECULAR INTERACTION; PREGNANCY; PREGNANCY DISORDER; PREGNANCY TEST; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; REVIEW; SPONTANEOUS ABORTION; SULFATION; SYNCYTIOTROPHOBLAST; TUMOR PROMOTION;

CARBOHYDRATE SEQUENCE; CHORIONIC GONADOTROPIN; FEMALE; GLYCOSYLATION; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PREGNANCY;

EID: 82955167925     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2011.09.037     Document Type: Review

References (174)

1. Elliott M.M., Kardana A., Lustbader J.W., Cole L.A. Carbohydrate and peptide structure of the α- and β-subunits of human chorionic gonadotropin from normal and aberrant pregnancy and choriocarcinoma. Endocrine 1997, 7:15-32.
2. Birken S., Maydelman Y., Gawinowicz M.A., Pound A., Liu Y., Hartree A.S. Isolation and characterization of human pituitary chorionic gonadotropin. Endocrinology 1996, 137:1402-1411.
3. Valmu L., Alfthan H., Hotakainen K., Birken S., Stenman U.H. Site-specific glycan analysis of human chorionic gonadotropin {beta}-subunit from malignancies and pregnancy by liquid chromatography-electrospray mass spectrometry. Glycobiology 2006, 16:1207-1218.
4. Morgan F.J., Birken S., Canfield R.E. The amino acid sequence of human chorionic gonadotropin. J Biol Chem 1975, 250:5247-5258.
5. Sutton J.M. Charge variants in serum and urine hCG. Clin Chem Acta 2004, 341:199-203.
6. Wehmann R.E., Nisula B.C. Metabolic and renal clearance rates of purified human chorionic gonadotropin. J Clin Invest 1981, 68:184-194.
7. Cole LA, Butler SA. Hyperglycosylated hCG, hCGß and Hyperglycosylated hCGß: Interchangeable Cancer Promoters. Molec Cell Endocrinol; in press.
8. Cole L.A., Butler S.A. The hCG receptor. Human chorionic gonadotropin (hCG) 2010, 139-146. Elsevier, Burlington MA. L.A. Cole (Ed.).
9. Cole L.A., Butler S.A. Structure, synthesis and function of hCG. Human chorionic gonadotropin (hCG) 2010, 49-66. Elsevier, Burlington MA. L.A. Cole (Ed.).
10. Laub M., Jennissen H.P. Identification of the anthelix motif in the TGF-ß superfamily by molecular 3D-Rapid Prototyping. Materialwiss Werkstofftech 2003, 34:1113-1119.
11. Lehnert S.A., Akhurst R.A. Embryonic expression pattern of TGF beta type-1 RNA suggests both paracrine and autocrine mechanisms of action. Development 1988, 104:263-273.
12. Lapthorn A.J., Harris D.C., Littlejohn A., Lustbader J.W., Canfield R.E., Machin K.J. Crystal structure of hCG. Nature 1994, 369:455-461.
13. Butler S.A., Ikram M.S., Mathieu S., Iles R.K. The increase in bladder carcinoma cell population induced by the free beta subunit of hCG is a result of an anti-apoptosis effect and not cell proliferation. Brit J Cancer 2000, 82:1553-1556.
14. Cole L.A. Hyperglycosylated hCG. Placenta 2007, 28:977-986.
15. Cole L.A., Butler S.A. Biological function of hyperglycosylated hCG. Human chorionic gonadotropin (hCG) 2010, 145-152. Elsevier, Burlington MA. L.A. Cole (Ed.).
16. Odell W.D., Griffin J. Pulsatile secretion of human chorionic gonadotropin in normal adults. N Engl J Med 1987, 317:1688-1691.
17. Odell W.D., Griffin J. Pulsatile secretion of chorionic gonadotropin during the normal menstrual cycle. J Clin Endocrinol Metab 1989, 69:528-532.
18. Cole L.A., Ladner D.G., Cole L.A., Gutierrez J.M. Production of hCG during the menstrual cycle. J Reprod Med 2009, 54:245-250.
19. Sasaki Y., Ladner D.G., Cole L.A. Hyperglycosylated hCG the source of pregnancy failures. Fertil Steril 2008, 89:1781-1786.
20. Cole L.A., Dai D., Butler S.A., Leslie K.K., Kohorn E.I. Gestational trophoblastic diseases: 1. Pathophysiology of hyperglycosylated hCG-regulated neoplasia. Gynecol Oncol 2006, 102:144-149.
21. Cole L.A., Khanlian S.A., Riley J.M., Butler S.A. Hyperglycosylated hCG (hCG-H) in gestational implantation, and in choriocarcinoma and testicular germ cell malignancy tumorigenesis. J Reprod Med 2006, 51:919-929.
22. Acevedo H.F., Hartstock R.J. Metastatic phenotype correlates with high expression of membrane-associated complete ß-human chorionic gonadotropin in vivo. Cancer 1996, 78:2388-2399.
23. Regelson W. Have we found the "definitive cancer biomarker"? The diagnostic and therapeutic implications of human chorionic gonadotropin-beta statement as a key to malignancy. Cancer 1995, 76:1299-1301.
24. Butler S.A. The molecular genetics of hCG. Human chorionic gonadotropin (hCG) 2010, 37-48. Elsevier, Burlington MA. L.A. Cole (Ed.).
25. Kovalevskaya G., Genbacev O., Fisher S.J., Cacere E., O'Connor J.F. Trophoblast origin of hCG isoforms: cytotrophoblasts are the primary source of choriocarcinoma-like hCG. Mol Cell Endocrinol 2002, 194:147-155.
26. Guibourdenche J., Handschuh K., Tsatsaris V., et al. Hyperglycosylated hCG is a marker of early human trophoblast invasion. J Clin Endocrinol Metab 2010, 95:E240-E244.
27. Handschuh K., Guibourdenche J., Tsatsari V., et al. Human chorionic gonadotropin produced by the invasive trophoblast but not the villous trophoblast promotes cell invasion and is down-regulated by peroxisome proliferator-activated receptor-a. Endocrinology 2007, 148:5011-5019.
28. Shi Q.J., Lei Z.M., Rao C.V., Lin J. Novel role of human chorionic gonadotropin in differentiation of human cytotrophoblasts. Endocrinology 1993, 132:387-395.
29. Toth P., Li X., Rao C.V., et al. Expression of functional human chorionic gonadotropin/human luteinizing hormone receptor gene in human uterine arteries. J Clin Endocrinol Metab 1994, 79:307-315.
30. Zygmunt M., Herr F., Keller-Schoenwetter S., et al. Characterization of human chorionic gonadotropin as a novel angiogenic factor. J Clin Endocrinol Metab 2002, 87:290-5296.
31. Lei Z.M., Reshef E., Rao C.V. The expression of human chorionic gonadotropin/ luteinizing hormone receptors in human endometrial and myometrial blood vessels. J Clin Endocrinol Metab 1992, 75:651-659.
32. Zygmunt M., Herr F., Keller-Schoenwetter S., et al. Characterization of human chorionic gonadotropin as a novel angiogenic factor. J Clin Endocrinol Metab 2002, 87:290-5296.
33. Rao C.V., Li X., Toth P., Lei Z.M., Cook V.D. Novel expression of functional human chorionic gonadotropin/luteinizing hormone receptor in human umbilical cords. J Clin Endocrinol Metab 1993, 77:1706-1714.
34. Wasowicz G., Derecka K., Stepien A., et al. Evidence for the presence of luteinizing hormone-chorionic gonadotrophin receptors in the pig umbilical cord. J Reprod Fertil 1999, 117:1-9.
35. Cole L.A. hCG and hyperglycosylated hCG in the establishment and evolution of hemochorial placentation. J Reprod Immunol 2009, 82:111-117.
36. Cole L.A., Khanlian S.A., Kohorn E.I. Evolution of the human brain, chorionic gonadotropin and hemochorial implantation of the placenta: insights into origins of pregnancy failures, preeclampsia and choriocarcinoma. J Reprod Med 2008, 53:449-557.
37. Schmitt E.J., Barros C.M., Fields P.A., et al. A cellular and endocrine characterization of the original and induced corpus luteum after administration of a gonadotropin-releasing hormone agonist or human chorionic gonadotropin on day five of the estrous cycle. J Anim Sci 1996, 74:1915-1929. M.
38. Richardson M.C., Masson G.M. Progesterone production by dispersed cells from human corpus luteum: stimulation by gonadotrophins and prostaglandin F2α; lack of response to adrenaline and isoprenaline. J Endocrinol 1980, 87:247-254.
39. Hirose T. Experimentalle histologische studie zur genese corpus luteum. Mitt Med Fakultd Univ ZU 1919, 23:63-70.
40. Akoum A., Metz C.N., Morin M. Marked increase in macrophage migration inhibitory factor synthesis and secretion in human endometrial cells in response to human chorionic gonadotropin hormone. J Clin Endocrinol Metab 2005, 90:2904-2910.
41. Wan H., Marjan A., Cheung V.W., et al. Chorionic gonadotropin can enhance innate immunity by stimulating macrophage function. J Leukocyte Biol 2007, 82:926-933.
42. Reshef E., Lei Z.M., Rao C.V., Pridham D.D., Chegini N., Luborsky J.L. The presence of gonadotropin receptors in nonpregnant human uterus, human placenta, fetal membranes, and decidua. J Clin Endocrinol Metab 1990, 70:421-430.
43. Zuo J., Lei Z.M., Rao C.V. Human myometrial chorionic gonadotropin/luteinizing hormone receptors in preterm and term deliveries. J Clin Endocrinol Metab 1994, 79:907-911.
44. Eta E., Ambrus G., Rao V. Direct regulation of human myometrial contractions by human chorionic gonadotropin. J Clin Endocrinol Metab 1994, 79:1582-1586.
45. Doheny H.C., Houlihan D.D., Ravikumar N., Smith T.J., Morrison J.J. Human chorionic gonadotrophin relaxation of human pregnant myometrium and activation of the BKCa channel. J Clin Endocrinol Metab 2003, 88:4310-4315.
46. Goldsmith P.C., McGregor W.G., Raymoure W.J., Kuhn R.W., Jaffe R.B. Cellular localization of chorionic gonadotropin in human fetal kidney and liver. J Clin Endocrinol Metab 1983, 57:54-61.
47. Rao C.V., Lei Z.M. The past, present and future of nongonadal hCG/LH actions in reproductive biology and medicine. Mol Cell Endocrinol 2007, 269:2-8.
48. McGregor W.G., Raymoure W.J., Kuhn R.W., Jaffe R.B. Fetal tissues can synthesize a placental hormone. Evidence for chorionic gonadotropin β-subunit synthesis by human fetal kidney. J Clin Invest 1981, 68:306-309.
49. Reis F.M., Cobellis L., Luisi S., Driul L., Florio P., Faletti A., et al. Paracrine/autocrine control of female reproduction. Gynecol Endocrinol 2000, 14:464-475.
50. Ticconi C., Zicari A., Belmonte A., Realacci M., Rao Ch.V., Piccione E. Pregnancy-promoting actions of HCG in human myometrium and fetal membranes. Placenta 2009, 28:S137-S143.
51. Schuster N., Krieglstein K. Mechanisms of TGF-β-mediated apoptosis. Cell Tissue Res 2002, 307:1-14.
52. Kamijo T., Rajabi M.R., Mizunuma H., Ibuki Y. Biochemical evidence for autocrine/paracrine regulation of apoptosis in cultured uterine epithelial cells during mouse embryo implantation in vitro. Molec Human Reprod 1998, 4:990-998.
53. Eder I.E., Stenzl A., Hobisch A., Cronauer M.V., Bartsch G., Klocker H. Transforming growth factors-β1 and β2 in serum and urine from patients with bladder carcinoma. J Urol 1996, 157:953-957.
54. Shooner C., Caron P.C., Fréchette-Frigon G., Leblanc V., Déry M.-C., Asselin E. TGF-beta expression during rat pregnancy and activity on decidual cell survival. Reprod Biol Endocrinol 2005, 3:20.
55. Liu Y.-X., Gao F., Wei P., et al. Involvement of molecules related to angiogenesis, proteolysis and apoptosis in implantation in rhesus monkey and mouse. Contraception 2005, 71:249-262.
56. Knittel T., Mehde M., Kobold D., Saile B., Dinter C., Ramadori G. Expression patterns of matrix metalloproteinases and their inhibitors in parenchymal and non-parenchymal cells of rat liver regulation by TNF-alpha and TGF-beta1. J Hepatol 1999, 30:48-60.
57. Murphy G., Reynolds J.J., Whitham S.E., Docherty A.J., Angel P., Heath J.K. Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor. Euro Molec Biol Org J 1987, 6:1899-1904.
58. Qureshi H.Y., Sylvester J., El Mabrouk M., Zafarullah M. TGF-beta-induced expression of tissue inhibitor of metalloproteinases-3 gene in chondrocytes is mediated by extracellular signal-regulated kinase pathway and Sp1 transcription factor. J Cell Physiol 2005, 203:345-352.
59. Stetler-Stevenson W.G., Brown P.D., Onisto M., Levy A.T., Liotta L.A. Tissue inhibitor of metalloproteinases-2 (TIMP-2) mRNA expression in tumor cell lines and human tumor tissues. J Biol Chem 1990, 265:13933-13938.
60. Staun-Ram E., Shaleu E. Human trophoblast function during the implantation process. Reprod Biol Endocrinol 2005, 3:56-68.
61. Fisher S.J., Tian-yi C., Li Z., et al. Adhesive and degradative properties of human placental cytotrophoblast cell in vitro. J Cell Biol 1989, 109:891-902.
62. Khoo N.K., Bechberger J.F., Shepherd T., et al. SV40 Tag transformation of the normal invasive trophoblast results in a premalignant phenotype I mechanisms responsible for hyperinvasiveness and resistance to anti-invasive action of TGFß. Intl J Cancer 1998, 77:429-439.
63. Cole L.A., Butler S.A., Khanlian S.A., et al. Gestational trophoblastic diseases: 2. Hyperglycosylated hCG as a reliable marker of active neoplasia. Gynecol Oncol 2006, 102:150-158.
64. Cole L.A., Muller Y. hCG in the management of quiescent and chemorefractory gestational trophoblastic diseases. Gynecol Oncol 2010, 116:3-9.
65. Butler S.A., Iles R.K. Biological function of the free ß-subunit: expression and treatment target in cancer. Human chorionic gonadotropin (hCG) 2010, 153-172. Elsevier, Burlington MA. L.A. Cole (Ed.).
66. Iles R.K. Ectopic hCGß expression by epithelial cancer: malignant behavior metastasis and inhibition of tumor cell apoptosis. Mol Cell Endocrinol 2007, 260:264-270.
67. Cole L.A., Birken S., Sutphen S., Hussa R.O., Pattillo R.A. Absence of the COOH-terminal peptide on ectopic human chorionic gonadotropin ß-subunit (HCG-ß). Endocrinology 1982, 110:2198-2200.
68. Butler S.A., Iles R.K. Ectopic human chorionic gonadotrophin ß secretion by epithelial tumors and human chorionic gonadotrophin ß-induced apoptosis in Karposi's sarcoma, is there a connection?. Clin Cancer Res 2003, 9:4666-4673.
69. Carter W.B., Sekharem M., Coppola D. Human chorionic gonadotropin induces apoptosis in breast cancer. Breast Cancer Res Treat 2006, 100:S243-S244.
70. Bellet D., Lazar V., Bleche I., Paradis V., Giovangrandi Y., Paterliru P. Malignant transformation of nontrophoblastic cells in association with the expression of chorionic gonadotropin ß genes normally transcribed in trophoblastic cells. Cancer Res 1997, 57:516-523.
71. Cosgrove D.E., Campain J.A., Cox G.S. Chorionic gonadotropin synthesis by human tumor cell lines: examination of subunit accumulation steady-state levels of mRNA and gene structure. Biochem Biophys Acta 1989, 1007:44-54.
72. Marcillac I., Cottu P., Theodore C., Lacombe M.J., Bellet D., Droz J.P. Free hCG beta subunit as tumour marker in urothelial cancer. Lancet 1993, 341:1354-1355.
73. Cole L.A. β-core fragment (β-core UGP or UGF). Tumor Marker Update 1994, 6:69-75.
74. Iles R.K. Human chorionic gonadotrophin and its fragments as markers of prognosis in bladder cancer. Tumor Marker Update 1995, 7:161-166.
75. Gillott D.J., Lles R.K., Chard T. The effects of β-human chorionic gonadotrophin on the in vitro growth of bladder cancer cell lines. Br J Cancer 1996, 73:323-326.
76. Acevedo H.F., Krichevsky A., Campbell-Acevedo E.A., Galyon J.C., Buffo M.J., Hartsock R.J. Flow cytometry method for the analysis of membrane-associated human chorionic gonadotropin, its subunits, and fragments on human cancer cells. Cancer 1992, 69:1818-1828.
77. Regelson W. Have we found the "definitive cancer biomarker"? The diagnostic and therapeutic implications of human chorionic gonadotropin-beta statement as a key to malignancy. Cancer 1995, 76:1299-1301.
78. Iles R.K. Human chorionic gonadotrophin and its fragments as markers of prognosis in bladder cancer. Tumor Marker Update 1995, 7:161-166.
79. Schwartz P.E., Chambers J.T., Taylor K.J., Cole L.A., Makuch R. Urinary gonadotropin fragments. Anticancer Res 1993, 13:1722-1725.
80. Muller C., Cole L.A. The quagmire of hCG and hCG testing in gynecologic oncology. Gynecol Oncol 2009, 112:663-672.
81. Rosen S.W., Calvert I., Weintraub B.D., Tseng J.S., Rabson A.S. Stimulation of N6O2'-dibutyryl cyclic adenosine 3':5'-monophosphate of ectopic production of the free beta subunit of chorionic gonadotropin by a human brain tumor cell line. Cancer Res 1980, 40:4325-4328.
82. Cook A.M., Huddart R.A., Jay G., Norman A., Dearnaley D.P., Horwich A. The utility of tumour markers in assessing the response to chemotherapy in advanced bladder cancer. Br J Cancer 2000, 82:1952-1957.
83. Cole L.A., Tanaka A., Kim G.S., et al. Beta-core fragment (beta-Core/UGF/UGP), a tumor marker: a 7-year report. Gynecol Oncol 1996, 60:264-270.
84. Acevedo H.F., Tong J.Y., Hartsock R.J. Human chorionic gonadotropin-beta subunit gene statement in cultured human fetal and cancer cells of different types and origins. Cancer 1995, 76:1467-1475.
85. Nishimura R., Baba S., Hasegawa K., et al. Characterization of immunoreactive hCG beta-subunit in cultured fluids of the cell lines derived from gynecologic malignant tumors. Nippon Sanka Fujinka Gakkai Zasshi 1990, 42:1471-1476.
86. Bepler G., Jaques G., Oie H.K., Gazdar A.F. Human chorionic gonadotropin and related glycoprotein hormones in lung cancer cell lines. Cancer Lett 1991, 58:145-150.
87. Ozturk M., Bellet D., Isselbacher K.J., Wands J. Ectopic beta-human chorionic gonadotropin production by a human hepatoma cell line (FOCUS): isolation and immunochemical characterization. Endocrinology 1987, 120:559-566.
88. Udagawa Y., Nozawa S., Chin K., et al. Biological properties of two newly established cell lines (SKG- 3a,3b) from a human uterine cervical epidermoid carcinoma. Nippon Sanka Fujinka Gakkai Zasshi 1984, 36:237-246.
89. Cole L.A., Schwartz P.E., Wong Y. Urinary gonadotropin fragments (UGF) in cancers of the female reproductive system: I Sensitivity and specificity comparison with other markers. Gynecol Oncol 1988, 31:82-90.
90. Szturmowicz M., Slodkowska J., Zych J., Rudzinski P., Sakowicz A., Rowinska-Zakrzewska E. Frequency and clinical significance of ß-subunit human chorionic gonadotropin expression in non-small cell lung cancer patients. Tumor Biol 1999, 20:99-104.
91. Kinugasa M., Nishimura R., Koizumi T., et al. Combination assay of urinary beta-core fragment of human chorionic gonadotropin with serum tumor markers in gynecologic cancers. Jpn J Cancer Res 1995, 86:783-789.
92. Ruddon R.W., Norton S.E. Use of biological markers in the diagnosis of cancers of unknown primary tumor. Semin Oncol 1993, 20:251-260.
93. Cole L.A., Kardana A., Andrade-Gordon P., et al. The heterogeneity of hCG: III. The occurrence, biological and immunological activities of nicked hCG. Endocrinology 1991, 129:1559-1567.
94. Delves P.J., Iles R.K., Roitt I.M., Lund T. Designing a new generation of anti-hCG vaccines for cancer therapy. Mol Cell Endocrinol 2007, 260:276-281.
95. Iversen P.L., Mourich D.V., Moulton H.M. Monoclonal antibodies to two epitopes of ß-human chorionic gonadotropin for the treatment of cancer. Curr Opin Mol Ther 2003, 5:156-160.
96. Moulton H.M., Yoshihara P.H., Mason D.H., Iversen P.L., Triozzi P.L. Active specific immunotherapy with ß-human chorionic gonadotropin peptide vaccine in patients with metastatic colorectal cancer: antibody response is associated with improved survival. Clin Cancer Res 2002, 8:2044-2051.
97. Morse M.A., Chapman R., Powderly J., et al. Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with toll-like receptor stimulation to induce immunity to self-antigens in cancer patients. Clin Cancer Res 2011, 17:4844-4853.
98. He L.-Z., Ramakrishna V., Connolly J.E., et al. A novel human cancer vaccine elicits cellular responses to the tumor-associated antigen, human chorionic gonadotropin β. Clin Cancer Res 2004, 10:1920-1924.
99. Triozzi P.L., Stevens V.C. Human chorionic gonadotropin as a target for cancer vaccines. Oncol Rep 1999, 6:7-17.
100. Lei Z.M., Taylor D.D., Gercel-Taylor C., Rao C.V. Human chorionic gonadotropin promotes tumorigenesis of choriocarcinoma JAR cells. Troph Res 1999, 13:147-159.
101. Hamade A.L., Nakabayashi K., Sato A., et al. Transfection of antisense chorionic gonadotropin ß gene into choriocarcinoma cells suppresses the cell proliferation and induces apoptosis. J Clin Endocrinol Metab 2005, 90:4873-4879.
102. Snyder J.A., Haymond S., Parvin C.A., Gronowski A.M., Grenache D.G. Diagnostic considerations in the measurement of human chorionic gonadotropin in aging women. Clin Chem 2005, 51:1830-1835.
103. Cowan B.D. Ectopic Pregnancy. Curr Opin Obstet Gynecol 1993, 5:328-332.
104. Jones R.E. Pregnancy, spontaneous abortion. Human reproductive biology 1991, 189-228. Academic Press Inc., San Diego CA. R.E. Jones (Ed.).
105. Heffner L.J. Pregnancy complications, early pregnancy loss. Reproduction at a Glance 2001, 86-91. Blackwell Science Ltd, Berlin, Germany. Blackwell Science (Ed.).
106. Sutton-Riley J.M., Khanlian S.A., Byrn F.W., Cole L.A. A single serum test for measuring early pregnancy outcome with high predictive value. Clin Biochem 2006, 39:682-687.
107. Semprini A.E., Simoni G. Not so efficient reproduction. Lancet 2000, 356:257-258.
108. Norwitz E.R., Schust D.J., Fisher S.J. Implantation and the survival of early pregnancy. New Engl J Med 2001, 345:1400-1408.
109. Cole LA. Pregnancy failures. Obstet Gynecol,; in press.
110. Ho H.H., O'Connor J.F., Nakajima S.T., Tieu J., Overstreet J.W., Lasley B.L. Characterization of human chorionic gonadotropin in normal and abnormal pregnancies. Early Pregn 1997, 3:213-224.
111. O'Connor J.F., Ellish N., Kakuma T., Schlatterer J., Kovalevskaya G. Differential urinary gonadotrophin profiles in early pregnancy and early pregnancy loss. Prenat Diagn 1998, 18:1232-1240.
112. Kovalevskaya G., Birken S., Kakuma T., et al. Differential expression of human chorionic gonadotropin (hCG) glycosylation isoforms in failing and continuing pregnancies: preliminary characterization of the hyperglycosylated hCG epitope. J Endocrinol 2002, 172:497-506.
113. Cole L.A., Khanlian S.A., Sutton J.M., Davies S., Stephens N. Hyperglycosylated hCG (invasive trophoblast antigen, ITA) a key antigen for early pregnancy detection. Clin Biochem 2003, 36:647-655.
114. Davies S., Byrn F., Cole L.A. Testing for early pregnancy viability and complications. Clin Lab Med 2003, 23:257-264.
115. Cole L.A., Shahabi S., Oz U.A., Bahado-Singh R.O., Mahoney M.J. Hyperglycosylated hCG (invasive trophoblast antigen) immunoassay: a new basis for gestational down syndrome screening. Clin Chem 1999, 45:2109-2119.
116. Weinans J.N., Butler S.A., Mantingh A., Cole L.A. Urinary hyperglycosylated hCG in first-trimester screening for chromosomal abnormalities. Prenat Diagn 2000, 20:976-978.
117. Bahado-Singh R.O., Oz A.U., Kingston J.M., Shahabi S., Hsu C.D., Cole L.A. The role of hyperglycosylated hCG in trophoblast invasion and the prediction of subsequent pre-eclampsia. Prenat Diagn 2002, 22:478-481.
118. Cole L.A., Dutroit S., Higgins T.N. Total hCG tests. Clin Chem Acta 2011, 412:2216-2222.
119. Cole L.A., Sutton J.M., Higgins T.N., Cembrowski G.S. Between method variation in human chorionic gonadotropin results. Clin Chem 2004, 50:873-888.
120. Cole L.A., Shahabi S., Butler S.A., et al. Utility of commonly used human chorionic gonadotropin immunoassays in the diagnosis and management of trophoblastic disease. Clin Chem 2001, 47:308-315.
121. Sturgeon C.M., Berger P., Bidart J.-M., et al. Differences in recognition of the 1st WHO international reference reagents for hCG-related isoforms by diagnostic immunoassays for human chorionic gonadotropin. Clin Chem 2009, 55:1484-1491.
122. Whittington J., Fantz C.R., Gronowski A.M., et al. The analytical specificity of human chorionic gonadotropin assays determined using WHO International Reference Reagents. Clin Chim Acta 2010, 411:81-85.
123. Cole L.A. "Background" human chorionic gonadotropin in healthy, nonpregnant women. Clin Chem 2005, 51:1765-1766.
124. Cole L.A., Laidler L., Muller C. USA hCG reference service, 10 year report. Clin Biochem 2010, 43:1013-1022.
125. Gronowowski A.M., Fantz C.R., Parvin C.A., et al. Use of serum FSH to identify perimenopausal women with pituitary hCG. Clin Chem 2008, 54:652-656.
126. Cole L.A., Ladner D.G. Background hCG in non-pregnant individuals: need for more sensitive point-of-care and over-the-counter pregnancy tests. Clin Biochem 2009, 42:168-175.
127. Cole L.A., Laidler L.L. Inherited hCG. J Reprod Med 2010, 55:99-102.
128. Cole L.A., Rinne K.M., Shahabi S., Omrani A. False positive hCG levels leading to unnecessary surgery and chemotherapy, and needless occurrences of diabetes and coma. Clin Chem 1999, 45:313-314.
129. Cole L.A., Khanlian S.A. Easy fix for clinical laboratories for the false positive defect with the Abbott AxSym total ß-hCG test. Clin Biochem 2004, 37:344-349.
130. Cole L.A., Cermik D., Bahado-Singh R. Oligosaccharide variants of hCG-related molecules: potential screening markers for Down syndrome. Prenat Diagn 1997, 17:1188-1190.
131. Kato Y., Braunstein G.D. Discordant secretion of placental protein hormones in differentiating trophoblasts in vitro. J Clin Endocrinol Metab 1989, 68:814-820.
132. Knöfler M. Regulation of hCG during normal gestation and in pregnancies affected by Down's syndrome?. Molec Human Reprod 1999, 5:895-897.
133. Frendo J.L., Vidaud M., Guibourdenche J., et al. Defect of villous cytotrophoblast differentiation into syncytiotrophoblast in Down's syndrome. J Clin Edcrinol Metab 2000, 85:3700-3707.
134. Newberger D.S. Down syndrome: prenatal risk assessment and diagnosis. Am Fam Physician 2000, 62:837-838.
135. Chard T., Lowings C., Kitau M.J. Alphafetoprotein and chorionic gonadotropin levels in relation to Down's syndrome. Lancet 1984, 29:750-751.
136. Bogart M.H., Pandian M.R., Jones O.W. Abnormal maternal serum chorionic gonadotropin levels in pregnancies with fetal chromosome abnormalities. Prenat Diagn 1987, 7:623-630.
137. Wald N.J., Cuckle H.S., Densem J.W., et al. Maternal serum unconjugated oestriol as an antenatal screening test for Down's syndrome. Br J Obstet Gynaecol 1988, 95:334-341.
138. Wald N.J., Densem J.W., Muttukvishna S., Knight P.G. Prenatal screening for Down syndrome using inhibin A as a serum marker. Prenat Diagn 1996, 16:143-153.
139. Macri J.N., Kasturi R.V., Krantz D.A., et al. Maternal serum Down syndrome screening: free beta protein is a more effective marker than human chorionic gonadotrophin. Am J Obstet Gynecol 1990, 163:1248-1253.
140. Nicolaides K.H., Azar G., Byrne D., Mansur C., Marks K. Fetal nuchal translucency: ultrasound screening for chromosomal defects in the first trimester of pregnancy. Br Med J 1992, 304:867-889.
141. Palomaki G.E., Knight G.J., Roberson M.M., et al. Invasive trophoblast antigen (hyperglycosylated human chorionic gonadotropin) in second-trimester maternal urine as a marker for Down syndrome: preliminary results of an observational study on fresh samples. Clin Chem 2003, 50:182-189.
142. Palomaki G.E., Knight G.J., Neveux L.M., Pandian R., Haddow J.E. Maternal serum invasive trophoblast antigen and first-trimester Down syndrome screening. Clin Chem 2005, 51:1499-1504.
143. Poon L., Leung T., Lau T., Lo Y. Prenatal detection of fetal Down syndrome from maternal plasma. Lancet 2000, 356:1819-1820.
144. Cole L.A. Human chorionic gonadotropin and associated molecules. Expert Rev Mol Diag 2009, 9:51-73.
145. Nisula B.C., Blithe D.L., Akar A., Lefort G., Wehmann R.E. Metabolic fate of human chorionic gonadotropin. J Steroid Biochem 1989, 33:733-737.
146. Strickland T.W., Puett D. The kinetic and equilibrium parameters of subunit association and dissociation. J Biol Chem 1982, 257:2954-2960.
147. Veldhuis J.D., Fraioli F., Rogol A.D., Dufau M.L. Metabolic clearance of biologically active luteinizing hormone in man. J Clin Invest 1986, 77:1122-1128.
148. Lefort G.P., Stolk J.M., Nisula B.C. Evidence that desialylation and uptake by hepatic receptors for galactose-terminated glycoproteins are immaterial to the metabolism of human choriogonadotropin in the rat. Endocrinology 1984, 115:1551-1557.
149. Van Hall E.V., Vaitukaitis J.L., Ross G.T., Hickman J.W., Ashwell G. Effects of progressive desialylation on the rate of disappearance of immunoreactive hCG from plasma in rates. Endocrinology 1971, 89:11-15.
150. Wide L., Hobson B. Some qualitative differences of hCG in serum from early and late pregnancies and trophoblastic diseases. Acta Endocrinol 1987, 116:465-472.
151. Wehmann R.E., Nisula B.C. Metabolic clearance rates of the subunits of human chorionic gonadotropin. J Clin Endocrinol Metab 1979, 48:753-759.
152. Cole L.A., Karadana A., Park S.-Y., Braunstein G.D. The deactivation of hCG by nicking and dissociation. J Clin Endocrinol Metab 1993, 76:704-715.
153. Karadana A., Cole L.A. Human chorionic gonadotropin β-subunit nicking enzymes in pregnancy and cancer patient serum. J Clin Endocrinol Metab 1994, 79:761-767.
154. Norman R.J., Buchholtz M.W., Somogyl A.A., Amato F. hCGbeta core fragment is a metabolite of hCG: evidence from the infusion of recombinant hCG. J Endocrinol 2000, 164:299-305.
155. Cole L.A. Evolution of hCG, evolution of humans and evolution of human pregnancy disorders and cancer. Human chorionic gonadotropin (hCG) 2010, Elsevier, Burlington MA, p. 383-376. L.A. Cole (Ed.).
156. Cole L.A. The pregnancy implantation, villous formationand hemochorial placentation. Human chorionic gonadotropin (hCG) 2010, 23-34. Elsevier, Burlington MA. L.A. Cole (Ed.).
157. Fiddes J.C., Goodman H.M. The cDNA for the ß-subunit of human chorionic gonadotropin suggests evolution of a gene by readthrough into the 3'-untranslated region. Nature 1980, 286:684-687.
158. Maston G.A., Ruvolo M. Chorionic gonadotropin has a recent origin within primates and an evolutionary history of selection. Mol Biol Evol 2002, 19:320-334.
159. Bambra C.S. Purification and properties of baboon chorionic gonadotropin. J Reprod Fertil 1987, 19:421-430.
160. Crawford R.J., Tegear G.W., Niall H.D. The nucleotide sequence of baboon chorionic gonadotropin ß-subunit genes have diverged from the human. Gene 1986, 46:161-169.
161. Cassels J.W., Mann K., Blithe D.L., Nisula R.C., Wehmann R.E. Reduced metabolic clearance of acidic variants of human choriogonadotropin from patients with testicular cancer. Cancer 1989, 64:2313-2318.
162. Rosa C., Amr S., Birken S., Wehmann R., Nisula B. Effect of desialylation of human chorionic gonadotropin on its metabolic clearance rate in humans. J Clin Endocrinol Metab 1984, 59:1215-1219.
163. Martin R.D. Relative brain size and basal metabolic rate in terrestrial vertebrates. Nature 1981, 293:57-60.
164. Gibbons A. Solving the brain's energy crisis. Science 1998, 280:1345-1347.
165. Robillard P.Y., Hulsey T.C., Chaouat G. Preeclampsia and human reproduction. An essay of a long term reflection. J Reprod Immunol 2003, 59:93-100.
166. Martin R.D. Scaling of the mammalian barrier: the maternal energy hypothesis. News Physiol Sci 1996, 4:149-154.
167. Cunnane S.C., Herbige L.S., Crawford M.A. The importance of energy and nutrient supply in human brain evolution. Nutr Health 1993, 9:19-35.
168. Martin R.D. Human reproduction: a comparative background for medical hypotheses. J Reprod Immunol 2003, 59:111-135.
169. Pjenenborg R. The placental bed. Hypertens Pregn 1996, 15:7-23.
170. Kliman H.J. Uteroplacental blood flow. The story of decidualization, menstruation, and trophoblast invasion. Am J Path 2000, 157:1759-1768.
171. Robillard P.Y., Chaline J., Chaouat G., Hulsey T.C. Preeclampsia/eclampsia and the evolution of the human brain. Curr Anthropol 2003, 44:130-135.
172. Jauniaux E., Poston L., Burton G.J. Placental-related diseases of pregnancy: involvement of oxidative stress and implications in human evolution. Hum Reprod Updt 2006, 12:747-755.
173. Lockett W.P. Comparative development and evolution of the placenta in primates. Contrib Primatol 1974, 3:42-234.
174. Human chorionic gonadotropin (hCG) 2010, 1-382. Elsevier, Burlington MA. L.A. Cole (Ed.).